November 18, 2026 · The American journal of psychiatry · DOI: 10.1176/appi.ajp.20260061

GLP-1 Receptor Agonists in Psychotic Disorders: Mechanistic Convergence and Therapeutic Implications for Brain and Metabolic Health.

Listen to this summary

This systematic review and narrative synthesis asks whether GLP-1 receptor agonists, which act on glucose, gut-brain, inflammatory, and reward pathways, could address the metabolic and neuropsychiatric burden of psychotic disorders. The authors find the clearest benefit for antipsychotic-associated weight gain and cardiometabolic risk, with suggestive but inconclusive effects on alcohol and nicotine use and no consistent improvement in psychotic symptoms, cognition, or functioning. They conclude that GLP-1RAs are a mechanistically grounded strategy for cardiometabolic burden in psychotic disorders, though current trials are small, short, and heterogeneous.

Thao D V Le, Onur Memetoglu, Julio E Ayala, Fei Du, Bruce Cohen, Dost Öngür, Virginie-Anne Chouinard

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play